Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd.
Your view on KSPHF
Overview
What the company does, where it operates, and who runs it.
About Kissei Pharmaceutical Co., Ltd.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mutsuo Kanzawa
- Headquarters
- 19-48, Yoshino, Matsumoto, JP
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mutsuo Kanzawa
- Headquarters
- 19-48, Yoshino, Matsumoto, JP
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan.
The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality.
Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients.
The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma.
In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services.
The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Kissei Pharmaceutical Co., Ltd., and the rating behind it. KSPHF last traded at $26.97, 11.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Kissei Pharmaceutical Co., Ltd.. Starting points for Kissei Pharmaceutical Co., Ltd.: P/E 11.8, EPS $337.31, beta -0.26 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Kissei Pharmaceutical Co., Ltd.. Kissei Pharmaceutical Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Kissei Pharmaceutical Co., Ltd.. Trailing twelve-month EPS for Kissei Pharmaceutical Co., Ltd. stands at $337.31. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Kissei Pharmaceutical Co., Ltd.. Kissei Pharmaceutical Co., Ltd. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Kissei Pharmaceutical Co., Ltd. valued side by side against its closest peers. Kissei Pharmaceutical Co., Ltd. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Kissei Pharmaceutical Co., Ltd., and how their positions are changing. At a $1.12B market value, institutional positions materially move Kissei Pharmaceutical Co., Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Kissei Pharmaceutical Co., Ltd. executives and directors. Shares of Kissei Pharmaceutical Co., Ltd. have traded between $23.23 and $31.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Kissei Pharmaceutical Co., Ltd.. Kissei Pharmaceutical Co., Ltd. is a $1.12B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Kissei Pharmaceutical Co., Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Kissei Pharmaceutical Co., Ltd.. Coverage tracks Kissei Pharmaceutical Co., Ltd. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.